Nyrada
Drug research and development
Short position
Nyrada (ASX:NYR) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 16 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.06% in September 2026. NYR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Nyrada (NYR) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $2.2MM (source: ASX (Markit))vs $2.6MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$6.6Mvs −$4.8M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.027T (source: Derived: trailing 12 months at year end)vs −$0.024 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −14.3%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −398.9%
- Net margin
- −298.9%
- FCF margin
- −206.2%
- ROE
- −100.0%
- ROA
- −83.4%
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 11.9×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $118.6M
- P/E
- n/a
- P/B
- 12.4×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $2.2MM (source: ASX (Markit)) | $2.6MM (source: ASX (Markit)) | $3.4MM (source: ASX (Markit)) | $1.6MM (source: ASX (Markit)) |
| Operating income | −$8.8M | −$7.4M | −$4.8M | −$9.4M |
| EBITDA | −$8.7M | −$7.4M | −$4.8M | −$9.4M |
| EBIT | −$8.8M | −$7.4M | −$4.8M | −$9.4M |
| Pretax income | −$6.6M | −$4.8M | −$1.4M | −$7.8M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$6.6M | −$4.8M | −$1.4M | −$7.8M |
| Net interest income | $182.1K | $162.1K | $161.0K | $148.8K |
| EPS basic | −$0.027T (source: Derived: trailing 12 months at year end) | −$0.024 | −$0.009 | −$0.050 |
| EPS diluted | −$0.027T (source: Derived: trailing 12 months at year end) | −$0.024 | −$0.009 | −$0.050 |
| Shares | 247.1M | 210.9M | 182.2M | 156.0M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Preliminary Final ReportAnnual Results18 Aug 2026via asx_announcements
- Annual Report for year ended 30 June 2026Annual Report18 Aug 2026via asx_announcements
- Nyrada Full Year Results FY2026Full Year Results18 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report15 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report to 31 December 2025Half Year Results18 Feb 2026via asx_announcements
- Nyrada Half Year FY2026 ResultsHalf Year Results18 Feb 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report23 Jan 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report21 Oct 2025via asx_announcements
- Preliminary Final ReportAnnual Results22 Aug 2025via asx_announcements
Showing 10 of 70 reports